Thus, we investigated the phosphorylation status of the DNA damage sensors ATM, H2AX and Chk2 in chemoresistant GBM cells (P3 and T98G) in response to BTZ and TMZ mono- or combination therapy. The gene discussed is CHEK2; the disease is glioblastoma.